Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design
about
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Measurement of Free Versus Total Therapeutic Monoclonal Antibody in Pharmacokinetic Assessment is Modulated by Affinity, Incubation Time, and Bioanalytical Platform.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS.
P2860
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@ast
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@en
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@nl
type
label
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@ast
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@en
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@nl
prefLabel
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@ast
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@en
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@nl
P2093
P2860
P356
P1476
Agonistic TAM-163 antibody tar ...... nd guide clinical trial design
@en
P2093
Cynthia Rohde
Mylene Perreault
Pratap Singh
Ruth E Gimeno
Yulia Vugmeyster
P2860
P304
P356
10.4161/MABS.23826
P407
P577
2013-01-01T00:00:00Z